MAFLD and risk of CKD

doi:10.1016/j.metabol.2020.154433

科研成果详情

题名	MAFLD and risk of CKD
作者	Sun, Dan-Qin 1,2,3; Jin, Yan 4; Wang, Ting-Yao 5; Zheng, Kenneth I.6; Rios, Rafael S.6; Zhang, Hao-Yang 7; Targher, Giovanni 8; Byrne, Christopher D.9; Yuan, Wei-Jie 3; Zheng, Ming-Hua6,10,11
发表日期	2021-02
发表期刊	METABOLISM-CLINICAL AND EXPERIMENTAL 影响因子和分区
语种	英语
原始文献类型	Article
关键词	Metabolic dysfunction-associated fatty liver disease Non-alcoholic fatty liver disease Chronic kidney disease
其他关键词	FATTY LIVER-DISEASE ; TYPE-2 DIABETIC-NEPHROPATHY ; CHRONIC KIDNEY-DISEASE ; CARDIOVASCULAR RISK ; NAFLD
摘要	Background/aims: Whereas nonalcoholic fatty liver disease (NAFLD) is a multisystem disease, the association between metabolic dysfunction-associated fatty liver disease (MAFLD) and extra-hepatic diseases is not known. The aim of this cross-sectional study was to compare the prevalence of chronic kidney disease (CKD) in patients with either MAFLD or NAILD, and then to examine the association between the presence and severity of MAFLD and CKD and abnormal albuminuria. Methods: A total of 12,571 individuals with complete biochemical and liver ultrasonography data from the Third National Health and Nutrition Examination Survey (1988-1994) were included in the analysis. Multivariable logistic regression analyses were performed to test the independence of associations between MAFLD or MAFLD severity as the key exposures and CKD (defined as either CKD stage >= or stage >= 3) or abnormal albuminuria (urinary albumin-to-creatinine ratio >= 3 mg/mmol) as the outcomes. Results: The prevalence of MAFLD and NAFLD was 30.2% (n = 3794) and 362% (n = 4552), respectively. MAFLD individuals had a lower eGFR (74.96 +/- 1821 vs. 76.46 +/- 18.24 ml/min/1.73 m(2), P < 0.001) and a greater prevalence of CKD (29.60% vs. 26.56%, P< 0.05) than NAFLD individuals. Similarly, there was a higher prevalence CKD in MAFLD than in non-metabolic dysfunction-associated NAFLD (P < 0.05). Notably, after adjustment for sex, age, ethnicity, alcohol intake and diabetes, the severity of MAFLD (i.e. NAFLD fibrosis score >= 0.676) was associated with 1.34-fold higher risk of prevalent CKD (P < 0.05). Conclusions: MAFLD identifies patients with CKD better than NAFLD. MAFLD and MAFLD with increased liver fibrosis score are strongly and independently associated with CKD and abnormal albuminuria. (C) 2020 Elsevier Inc. All rights reserved.
资助项目	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [82070588, 82000690]; High Level Creative Talents from Department of Public Health in Zhejiang Province [S2032102600032]; Project of New Century 551 Talent Nurturing in Wenzhou; Wuxi Youth Talent Fund [QNRC075]; Youth Research Project Fund from Wuxi Municipal Health Commission [Q201932]; Top-notch Talents from Young and Middle-Age Health Care in Wuxi; University School of Medicine of Verona, Verona, Italy; Southampton NIHR Biomedical Research Centre, UK [IS-BRC-20004]
出版者	W B SAUNDERS CO-ELSEVIER INC
出版地	PHILADELPHIA
ISSN	0026-0495
EISSN	1532-8600
卷号	115
DOI	10.1016/j.metabol.2020.154433
页数	7
WOS类目	Endocrinology & Metabolism
WOS研究方向	Endocrinology & Metabolism
WOS记录号	WOS:000608790700018
收录类别	SCIE ; SCOPUS ; PUBMED
URL	查看原文
PubMed ID	33212070
SCOPUSEID	2-s2.0-85097091914
ESI高被引论文	2021-07 ; 2021-09 ; 2021-11 ; 2022-01 ; 2022-03 ; 2022-05 ; 2022-07 ; 2022-09 ; 2022-11 ; 2023-01 ; 2023-03 ; 2023-05 ; 2023-07 ; 2023-09 ; 2023-11 ; 2024-01 ; 2024-03 ; 2024-05 ; 2024-07 ; 2024-09
通讯作者地址	[Zheng, Ming-Hua]NAFLD Research Center,Department of Hepatology,the First Affiliated Hospital of Wenzhou Medical University,No. 2 Fuxue Lane,Wenzhou,325000,China
Scopus学科分类	Endocrinology, Diabetes and Metabolism;Endocrinology
TOP期刊	TOP期刊
引用统计	被引频次：86[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/20148
专题	附属第一医院第一临床医学院（信息与工程学院）、附属第一医院附属第一医院_肾内科
通讯作者	Zheng, Ming-Hua
作者单位	1.Affiliated Wuxi Clinical College of Nantong University,Wuxi,China; 2.Department of Nephrology,the Affiliated Wuxi No.2 People's Hospital of Nanjing Medical University,Wuxi,China; 3.Department of Nephrology,Shanghai General Hospital of Nanjing Medical University,Shanghai,China; 4.Department of Gastroenterology,the Affiliated Wuxi No.2 People's Hospital of Nanjing Medical University,Wuxi,China; 5.Department of Nephrology,the First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China; 6.NAFLD Research Center,Department of Hepatology,the First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China; 7.School of Biomedical Engineering,Sun Yat-sen University,Guangzhou,China; 8.Section of Endocrinology,Diabetes and Metabolism,Department of Medicine,Azienda Ospedaliera Universitaria Integrata Verona,Verona,Italy; 9.Southampton National Institute for Health Research Biomedical Research Centre,University Hospital Southampton,Southampton General Hospital,Southampton,United Kingdom; 10.Institute of Hepatology,Wenzhou Medical University,Wenzhou,China; 11.Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province,Wenzhou,China
通讯作者单位	附属第一医院; 第一临床医学院（信息与工程学院）、附属第一医院
推荐引用方式 GB/T 7714	Sun, Dan-Qin,Jin, Yan,Wang, Ting-Yao,et al. MAFLD and risk of CKD[J]. METABOLISM-CLINICAL AND EXPERIMENTAL,2021,115.
APA	Sun, Dan-Qin., Jin, Yan., Wang, Ting-Yao., Zheng, Kenneth I.., Rios, Rafael S.., ... & Zheng, Ming-Hua. (2021). MAFLD and risk of CKD. METABOLISM-CLINICAL AND EXPERIMENTAL, 115.
MLA	Sun, Dan-Qin,et al."MAFLD and risk of CKD".METABOLISM-CLINICAL AND EXPERIMENTAL 115(2021).